AstraZeneca Pharma Q4 Results 2025: Net Profit Rises 48% YoY to Rs 58.25 Cr, Revenue Grows 25%

AstraZeneca Pharma India Limited reported a strong financial performance for the fourth quarter ended March 31, 2025. The company's consolidated net profit rose by 48% year-on-year, reaching Rs 58.25 crore for the quarter.

AstraZeneca Pharma Q4 Results 2025

Revenue from operations of the major pharmaceutical company also saw healthy growth, increasing by 25.3% YoY to Rs 480.48 crore. AstraZeneca noted robust performance across its therapeutic segments, contributing to a 32% rise in full-year revenue compared to the previous fiscal. Additionally, profit before tax (PBT) for the quarter came in at Rs 84.15 crore, up from Rs 54.36 crore in the corresponding quarter of the previous year.

AstraZeneca Pharma India Limited Chief Financial Officer (CFO) and Director announced, "FY2024-25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32 per cent. This reflects our strategic focus on science, specialists, and the strength of our innovation-led portfolio. As we scale impact across therapy areas, we remain committed to delivering sustainable value to the people, society, and the planet."

In the fourth quarter of FY25, AstraZeneca Pharma India's oncology segment delivered strong performance, generating revenue of Rs 315.85 crore, which marks a 31.62% increase compared to the same period last year.

Revenue from the biopharmaceuticals division-which includes cardiovascular, renal, metabolism, respiratory, immunology, and vaccine therapies-also recorded modest growth of 1.9% year-on-year, reaching Rs 122.74 crore. Meanwhile, the rare disease segment saw a notable jump, with revenue rising to Rs 2 crore in Q4 FY25, up from Rs 0.17 crore in Q4 FY24, reflecting a significant expansion in this emerging area of focus.

Sanjeev Panchal, Country President and Managing Director of the company, "We are pleased to share that our company has, for the first time, crossed the Rs 1,700 crore mark ($200 million). Science is sustaining and growing the success of our company, helping us transform the future of healthcare, and the health of people, society, and the planet."

AstraZeneca Pharma Share Price Today

As of the market close on May 30, 2025, shares of AstraZeneca Pharma India were trading at Rs 7,980 apiece on the National Stock Exchange (NSE), reflecting a 0.78% gain compared to the previous trading session.